T A B L E O F C O N T E N T S B A C K G R O U N D
Sexually transmitted infections (STIs), including chlamydia, syphilis, trichomoniasis, gonorrhoea, herpes simplex virus (HSV), human papilloma virus (HPV), hepatitis B and HIV continue to be a major cause of concern globally including in high-, middle-and low-income countries. The four most common curable STIs worldwide are trichomoniasis (143 million estimated cases a year), chlamydia (131 million), gonorrhoea (78 million) and syphilis (5.6 million) (Newman 2015; WHO 2015) . In 2013, chlamydia infection was the most notified infection in the USA with a total of 1,401,906 infections, followed by 333,004 cases of gonorrhoea, 17,375 cases of primary and secondary syphilis and 348 cases of congenital syphilis (CDC 2014) . Similarly, chlamy-dia is the highest notified infection in Australia where there were 86,136 cases of chlamydia, 15,786 cases of gonorrhoea and 1999 cases of infectious syphilis in 2014 (Kirby 2015). Europe had a total of 384,555 cases of chlamydia reported from 16 European Union (EU) Member States, followed by 52,995 gonorrhoea cases reported from 28 states and 22,237 syphilis cases from 29 states (ECDC 2015) . There is also a high incidence of STIs in developing countries with an estimated 92.6 million cases in the World Health Organization (WHO) African Region, 78.5 million in the WHO South-East Asia Region, and 128.2 million in the WHO Western Pacific Region (WHO 2012).
Trichomoniasis is not a notifiable infection in any country (Poole 2013), but it is the most prevalent STI in the USA affecting 3.7 million people (Satterwhite 2013). Trichomonas vaginalis (T vaginalis) prevalence rates vary markedly by population and region, being as high as 50% in rural clinics in South Africa (Bowden 2000) , 16 .1% among rural Indigenous communities in Australia (Garrow 2002) and 7.2% among disadvantaged urban Indigenous communities in Australia (Panaretto 2006), and as low as 0.4% at an urban sexual health centre in Sydney, Australia (Uddin 2011). Between 2009 and 2011 there were over 16,000 episodes of trichomoniasis in England. However, this is an underestimate of the general population prevalence because these tests were limited to people attending genitourinary medicine clinics, as asymptomatic people are not routinely screened for T vaginalis infection (Mitchell 2014). Rates of infection were highest in patients of black ancestry (Caribbean and otherwise) with just under half of the clients residing in poor areas of England. Women were 15 times more likely to be diagnosed with the infection compared to men (Mitchell 2014).
STIs are of concern because of the significant morbidity they cause, their long-term impact on reproductive and perinatal health, and their social, economic and psychological impact (WHO 2012), as well as their capacity to facilitate the transmission of HIV infection (Fleming 1999; Ward 2010). STIs particularly cause high levels of morbidity among adolescents, young adults and marginalized and vulnerable communities, with the highest burden of disease among people aged less than 25 years. Sixty eight per cent of chlamydia cases in USA were among young people aged between 15 and 24 years, and rates among black and American Indians/ Alaska Natives were 6.4 and 4 times the rate among white Americans, respectively (CDC 2014). In Europe, 67% of chlamydia cases and 39% of gonorrhoea cases were among persons aged from 15 to 24 years (ECDC 2015) . In Australia the majority of chlamydia diagnoses (78%) and gonorrhoea diagnoses (57%) were also among 15 to 29 year olds. It is noteworthy that the rates among Indigenous Australians of chlamydia, gonorrhoea and syphilis are 3 times, 18 times and 4 times higher respectively, compared to non-Indigenous Australians (Kirby 2015).
Description of the condition
Chlamydiae are obligate intracellular bacteria that grow in eukaryotic cells and require resources from the host cells for their metabolism and replication (Peeling 1996) . Chlamydia trachomatis Serovars D-K species are associated with acute urethritis, cervicitis, pelvic inflammatory disease (PID), Reiters syndrome, Fitz-Hugh Curtis syndrome, and sequelae in women include ectopic pregnancy, chronic pelvic pain and tubal infertility (Peeling 1996) . In males, sequelae include proctitis and epididymo-orchitis. Chlamydia is also associated with adverse outcomes in pregnancy including preterm labor, low birth weight (LBW), neonatal death and premature rupture of membranes (PROM) (Peipert 2003) . Infants born to mothers infected with chlamydia can present with oph-thalmia neonatorum or neonatal pneumonia, and other mucous membranes can be infected including the oropharynx, urogenital tract and rectum (CDC 2015) . Females infected with chlamydia may present with a vaginal discharge or bleeding between periods, and males with urethritis and epididymitis (Donovan 2004); however up to 80% of infections are asymptomatic (Peipert 2003) . In females, chlamydia can be isolated from first-catch urine (FCU) and endocervical or vaginal swabs, though FCU is not as sensitive as endocervical or vaginal swabs. In males, FCU or urethral swabs can be used to test for chlamydia (ASHA 2014) . Nucleic acid amplification tests (NAAT) are highly sensitive for detecting chlamydia organisms (CDC 2015) . Recommended regimens for treatment of chlamydia include azithromycin 1 gm orally as a single dose, or doxycycline 100 mg orally twice a day for 7 days; alternative regimens include erythromycin, levofloxacin or ofloxacin. Neisseria gonorrhoeae (N. gonorrhoeae) is a Gram-negative intracellular obligate bacterium (Ng 2005). Gonococcal infections are associated with cervicitis, urethritis, pharyngitis, proctitis, PID, epididymitis and prostatitis; sequelae include chronic pelvic pain and tubal infertility in women, and urethral stricture in men (Ng 2005) . N. gonorrhoeae is also associated with disseminated infection in adults presenting as cutaneous lesions, tenosynovitis and arthritis (Belkacem 2013). In infants, N. gonorrhoeae is associated with ophthalmia neonatorum and neonatal sepsis, arthritis, meningitis, rhinitis, vaginitis and urethritis (CDC 2015). Clinically, gonococcal infections tend to be more severe than chlamydia; however a large proportion of both females and males can be asymptomatic or undiagnosed (Chandeying 2000; Turner 2002). Specimens for testing for N. gonorrhoeae depend on the age, sex and sexual orientation of the patient and include urethral, cervical, vaginal, oropharyngeal, rectal and conjunctival specimens with culture and NAAT tests being highly sensitive in detecting N. gonorrhoeae. High levels of antimicrobial resistance in many countries have resulted in a change to recommended regimens for treatment of N. gonorrhoeae infections; combination therapy including ceftriaxone 250 mg intramuscular (IM) in a single dose with azithromycin 1 g orally in a single dose is recommended for uncomplicated gonococcal infections of the cervix, urethra, pharynx and rectum (CDC 2015). Syphilis, a systemic infection, is caused by Treponema pallidum, a Gram-negative spirochaete bacterium. It is associated with spontaneous abortions, stillbirths, prematurity and congenital syphilis (Genc 2000). The disease is categorised into three stages (primary, secondary and tertiary syphilis) and two latent phases (early and late latent infections) (CDC 2015). As an acquired infection, syphilis first presents as a chancre at the site of inoculation after an incubation period of 3 to 90 days, this constituting the primary stage of syphilis (Genc 2000) . The chancre may present on the genitalia, or oral or rectal mucosa, and spontaneously resolves after about six weeks. Secondary syphilis may manifest as skin rash, mucocutaneous lesions or generalised lymphadenopathy and, if un-treated, goes into a latent phase (a period of no clinical manifestations). The latent phase may last for several years and can develop into more severe systemic disease with cardiac, skin and skeletal manifestations, this constituting the tertiary stage of syphilis (Genc 2000) . Latent infection with syphilis is divided into early latency (one year or less from time of infection) and late latency (more than one year since infection). Any stage of syphilis can be complicated by central nervous system (CNS) involvement, i.e. neurosyphilis, or even ocular manifestations. CNS manifestations include cognitive dysfunction, cranial nerve palsies, meningitis and stroke (CDC 2015). Syphilis can be diagnosed using lesion exudates and tissue samples from the primary chancre, or serological tests (CDC 2015). A definitive diagnosis of syphilis infection requires at least two serological tests. The traditional algorithm includes screening with a nontreponemal test, e.g. Venereal Disease Research Laboratory (VDRL) or Rapid Plasma Reagin (RPR), followed by a confirmatory treponemal test, e.g. Treponema pallidum haemagglutination assay (TPHA), Treponema pallidum particle agglutination assay (TPPA), fluorescent treponemal antibody absorbed (FTA-ABS) tests, or enzyme immunoassays (EIAs) (PAHO 2015). All stages of syphilis can be treated using parenteral penicillin G, but the dosage, preparation and length of treatment will depend on the stage and manifestations of the disease. In the early phase, the purpose of treatment is to prevent sexual and mother-to-child transmission, but in the latent phase the purpose is to prevent complications and prevent mother-to-child transmission of syphilis (CDC 2015) . The recommended regimen for adults with primary, secondary and early latent syphilis is 2.4 million units of IM benzathine penicillin in a single dose, and for those with late latent syphilis or latent syphilis of unknown duration, the regimen is 2.4 million unit IM once a week for 3 weeks. The recommended regimen for tertiary syphilis with normal cerebral spinal fluid (CSF) examination is 3 doses of 2.4 million units of benzathine penicillin G IM at one-week intervals; while the recommended regimen for neurosyphilis and ocular syphilis is aqueous crystalline penicillin G 18 to 24 million units per day administered as 3 to 4 million units intravenously (IV) every 4 hours or continuous infusion, for 10 to 14 days (CDC 2015). Trichomonas vaginalis (T vaginalis) is a motile anaerobic flagellated parasite which attaches to vaginal epithelial cells but can also be isolated from the cervix, urethra, upper genital tract and the peritoneum. The parasite is associated with high levels of inflammation in the vaginal and urethral mucosa, tissue damage and long-term sequelae (Coleman 2013). Trichomoniasis is also associated with PID, low birth weight, and preterm delivery (Cotch 1997; Johnston 2008). Trichomoniasis may cause vaginitis, presenting as a foul smelling frothy yellow-green discharge and vulvar itching in females, and as balanitis and urethritis in males (Swygard 2004); however a majority of infections are asymptomatic (Bowden 2000). T vaginalis is transmitted via sexual contact and vertically to infants during vaginal delivery, with an incu-bation period of between 4 and 18 days. The organism can be detected from vaginal, endocervical, urethral, semen and urine specimens using wet mount microscopy, NAAT tests, antigen tests or culture, though NAAT tests are more sensitive than culture. The recommended regimen for treatment of trichomoniasis is 2 g of metronidazole orally or tinidazole 2 g orally in a single dose. An alternative regimen is 500 mg of metronidazole orally twice a day for seven days (CDC 2015).
Description of the intervention
For the purpose of this review, a quality improvement (QI) intervention is defined as "any (health service) intervention aimed at reducing the quality gap for a group of patients representative of those encountered in routine practice" (Shojania 2004). The quality gap is the "difference between healthcare processes or outcomes observed in practice, and those thought to be achievable with the most current and effective professional knowledge, the difference [being] attributable in whole or in part to a deficiency that could be addressed by the healthcare system" (Shojania 2004). Quality improvement processes use systems thinking, data analysis and teams of professionals to bring about better outcomes for patients and improved clinical processes (Plsek 1999). A QI intervention could: be targeted at the implementation of a particular process of care or set of processes to benefit patients with a condition; increase the proportion of patients receiving recommended care; target implementation of a structural or organisational feature; attempt to improve outcomes for a broad group of patients; or target a subset of patients that is typically excluded from clinical re- Professional interventions are those that specifically target health professionals and include distribution of educational materials, educational meetings, local consensus processes, educational outreach visits, local opinion leaders, patient-mediated interventions, audit and feedback, reminders, marketing and mass media (EPOC 2002) . Educational meetings are one of the most common forms of professional interventions and vary in content, type and number of participants, length, frequency and targeted practices (Forsetlund 2009). Educational meetings consist of small or large group sessions and use a multitude of methods to enhance their effectiveness including vignettes, clinical scenarios, standardised patients and simulation. Educational meetings can be further supported using distance education and self-directed learning (Straus 2013). Distribution of educational materials, including printed or published clinical guidelines, journal articles and monographs, is another well-established, accessible, inexpensive, yet passive, QI professional intervention (Giguere 2012). Educational outreach vis-its, also known as academic detailing or public interest detailing, involve the use of trained personnel to deliver educational information to health professionals in their own practice setting, with the intention to change their professional practice (OBrien 2007). Used in conjunction with other interventions, educational outreach visits may include an assessment of barriers to evidencebased practice, tailoring of the intervention to those identified barriers, use of a respected professional to deliver the intervention and feedback on health professionals' clinical practice (Straus 2013). Audit and feedback (AF) is also another commonly used professional intervention albeit with variable results (Ivers 2012). AF is defined as "the development of a summary of some aspect of clinical performance over a specific period of time and subsequent provision of that information to individual practitioners, teams or health care organisations" (Brehaut 2012). AF is based on various theories including Diffusion of Innovations and Social Cognition Theories, Theory of Reasoned Action, Theory of Planned Behaviour (Colquhoun 2013) and Feedback Intervention Theory (Kluger 1996) . Other professional interventions include computer reminders that serve to prompt health professionals as they are engaged in the target activity such as when they are prescribing medicine, documenting the clinical encounter in the medical record or ordering investigations (Shojania 2009). Reminders assist the health professional to recall information that is relevant to the task at hand so that the client receives the best possible care. Local consensus processes involve the inclusion of health providers in decision-making processes and it is believed that a sense of ownership may enhance commitment to change and improvement processes (Nasser 2007). Use of local opinion leaders is based on Social Learning Theory whereby people who are seen as credible, competent and trustworthy are deemed possible change agents through their ability to influence and facilitate health professional behaviour change (Flodgren 2011; Grol 2007). Patient-mediated interventions, which include patient decision aids, communication skills training to patients and professionals, and patients' reports to health professionals, also aim to enhance evidence-based practice among health professionals through patient-provider interactions (EPOC 2002b; Straus 2013). Other professional interventions include mass media, e.g. use of radio, television and newspapers to reach a large number of health professionals, and marketing, which includes surveys and focus groups, targeting a range of providers (EPOC 2002b). Financial interventions target both individual health providers and institutions, and include payments, incentives and penalties. Financial interventions to providers include 'fee for service', where a provider is paid for the number and type of services delivered; capitation, where a provider is paid a set amount per patient for providing specific care; and provider salaried service, where a provider receives a basic salary for providing specific type of care to patients (EPOC 2002) . Institution financial interventions include institution incentives, grants or penalties where the institution or group of providers receive direct or indirect financial penalties for inappropriate behaviour (EPOC 2002b). Organisational interventions include provider-orientated interventions (revision of professional roles, clinical multidisciplinary teams, formal integration of services, skills mix changes) and structural interventions (changes in settings/site of service delivery, changes in medical records systems, organisation of quality monitoring mechanisms). Regulatory interventions include any interventions that aim to change service delivery or costs by regulation or law, including changes in medical liability, management of patient complaints, peer review or licensure (EPOC 2002) . This review will assess professional, financial, organisational and regulatory interventions targeting health systems and providers, but will exclude interventions specifically targeting patients such as patient incentives or user fees.
How the intervention might work
For STIs, QI interventions aim to: increase levels of screening for asymptomatic infections to identify and treat those with the infection; provide early treatment of those with infection in order to break the chains of transmission; enhance contact tracing to prevent reinfection and onward transmission and ensure notification of diseases to support monitoring and surveillance (Low 2006). Other STI QI interventions seek to enhance the rescreening of clients who have previously presented with an STI, as studies have demonstrated that a past history of an STI is highly predictive of recurrent infection (Peterman 2006; Turner 2010). In the USA, it is recommended that all sexually-active females aged below 25 years should be routinely screened for chlamydia and gonorrhoea on an annual basis and that sexually-active young men in clinical settings with high prevalence of chlamydia should also be routinely screened, including in sexually transmitted disease (STD) clinics and correctional facilities (CDC 2015). Screening for chlamydia and gonorrhoea is also recommended for older women who are at risk of infection, including those with a new partner, those with more than one sexual partner or those who are a contact of someone else with an STI. Universal screening for trichomoniasis is generally not recommended but advised only for women presenting with a vaginal discharge and those receiving care in high-prevalence settings such as STD clinics and correctional facilities (CDC 2015). The United States Preventive Services Task Force (USPSTF) does not recommend routine screening for syphilis among asymptomatic persons who are not at increased risk, due to the potential harms of screening such as costs, false positives and labelling/stigma (USPSTF 2014). Syphilis screening is only recommended for those at high risk and pregnant women at the first prenatal visit because of its high association with stillbirths, neonatal deaths and other complications (USPSTF 2009). Furthermore, Centers for Disease Control and Prevention (CDC) guidelines recommend that any person who tests positive for chlamydia or gonorrhoea and women who test positive for trichomoniasis should be rescreened at three months after treatment (CDC 2015). All of the aforementioned activities aim to reduce the transmission rates and overall burden of infection and associated complications. For instance, studies have found that screening for chlamydia in non-pregnant, high-risk females reduces the prevalence of chlamydia and the incidence of PID (Ostergaard 2000; Scholes 1996). Other studies have found that screening and treatment of chlamydia in pregnant women improves outcomes for both mother and child (Meyers 2007). Overall the aim of QI interventions targeting health services is to improve the clinical practice of the health providers in line with best practice guidelines, and effect organisational change in order to facilitate effective processes of care (Grol 2007). Interventions aim to facilitate changes that lead to better patient outcomes and system performance (Batalden 2007). However, how these interventions work will depend on the type of intervention, the context or external factors, the goal of the intervention, the target group/ population, and the characteristics of the health service and service providers (see Grol 2007 for detailed theoretical underpinnings of various QI interventions). For instance, professional interventions aim to: increase knowledge of best practice among providers by increasing access to educational materials and attendance at educational meetings and through educational outreach visits; influence practice through local opinion leaders who are 'educationally influential'; provide reminders to prompt health professionals; or provide a mechanism for audit and feedback (AF) (EPOC 2002b). Educational meetings impact on health professionals' competence and performance and ultimately on patient and population health outcomes by increasing health professionals' knowledge of best practice versus their current practice (Straus 2013). Pathman et al (Pathman 1996) describe a four-stage model -awareness, agreement, adoption and adherence; stages through which physicians progress in order for change to be adopted and sustained. As stated above, educational meetings may use a range of methods but it is generally accepted that more interactive workshops are more effective in changing clinical practice compared to didactic sessions (Straus 2013). Similarly, education materials aim to increase knowledge around best practice, however the effectiveness of these materials on health professionals' behaviour will depend on: the source of the material (its credibility and proximity to the health professionals); the channel (mode, frequency and duration); the message (clinical area, targeted behaviour, purpose and level of evidence); and the format (presentation, appearance and length) (Giguere 2012). AF works through various mechanisms including enhancing practitioners' awareness of their current practice in relation to desired performance (Straus 2013), and changing norms and setting goals for change (Ivers 2012). However, as an intervention, AF is also influenced by other factors including quality of data provided, motivation of health providers, organisational support, other contextual variables and whether the feedback draws attention to the task or to the individual practitioner (Ivers 2012; Kluger 1996).
In addition, prerequisites for effective feedback include timeliness, individualisation, non-punitiveness and, to a lesser degree, customisation of the feedback (Hysong 2012). Financial incentives act as an extrinsic source of motivation to effect behaviour change which may result in the desired change, but may inadvertently create a disincentive or other undesirable effects such as falsifying of reports, increase in quantity but not quality of care, or neglect of non-incentivised conditions/diseases (Straus 2013). In contrast, with organisational interventions, the focus is not on changing the individual's behavior, whether of the professional or patient, but on reforming the system and changing the structure of delivery of care, because inadequate performance is seen not as a failure of an individual, but as a failure of the system ( Grol 2007). Importantly, for all of the interventions discussed here, a range of factors interacting at the patient, health professional, organisational, economic and political levels will determine the effectiveness of interventions and a proper assessment of these factors must be made prior to implementation (Grol 2007). Other reviews have assessed the effectiveness of single QI interventions on professional practice, for instance AF (Ivers 2012) and continuous quality improvement strategies (Brennan 2013). One Cochrane review assessed the effectiveness of a range of partner notification strategies for people with STIs (Ferreira 2013) and another has been proposed to assess interventions for screening for chlamydia (Low 2013); however both reviews do not specifically assess the effectiveness of QI interventions on detection and management of curable STIs within primary care. A non-Cochrane systematic review assessed the efficacy of interventions targeting health services and patients in increasing screening for chlamydia, and found that significant increases in testing rates among females were associated with multifaceted interventions (relative risk (RR) 2.8 (95% confidence interval (CI) 2.4 to 3.2) (Guy 2011); smaller increases in testing rates were associated with other interventions such as computer reminders (odds ratio (OR) 1.3, 95% CI 1.1 to 1.4), linking chlamydia screening with Pap smears (OR 2.1, 95% CI 1.3 to 3.4) and interactive educational workshops for clinical staff (RR 1.0, 95% CI 0.8 to 1.2). Screening rates in males were significantly associated with a multifaceted quality improvement program that consisted of educational meetings for clinicians, audit and feedback and development of clinical teams (RR 3.0, 95% CI 2.5 to 3.5) and a directive to all doctors to test all males aged 16 to 25 years (RR 7.7, 95% CI 6.6 to 9.0). However this review was limited to chlamydia, to high-income countries and to English language publications. In addition, this review used a restricted definition of primary care, describing it as a health service that provides the first point of entry of care and as the ongoing focal point for all the patient's healthcare requirements. This definition potentially excludes other providers of primary care in low-income countries such as hospitals and other primary care service providers who may not be the ongoing focal point for all of the patient's healthcare requirements. Similarly another non-Cochrane review assessed the effectiveness of interventions in increasing rescreening for repeat chlamydia infection (Guy 2012). Mailed screening kits and reminders were most significantly associated with increased rescreening rates, however again this review was limited to chlamydia. In addition, both of these reviews were limited to screening which is only one aspect of sexual health service delivery. This review therefore seeks to add to the existing knowledge about effective QI interventions designed to improve health providers' practice in the detection and management of the four most common curable STIs and also those designed to improve the broader health system's responsiveness to detection and management of these STIs. The review proposes to determine the effectiveness of STI QI interventions within primary care facilities and with primary care providers in order to resolve any conflicting evidence, explore the effectiveness of interventions in different settings and thus provide a basis for decision-making in these contexts.
Why it is important to do this review

O B J E C T I V E S
To assess the effectiveness and safety of quality improvement interventions for the detection and management of curable sexually transmitted infections in primary care.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all published and unpublished randomised controlled trials (RCTs) including cluster-randomised trials and crossover trials. Since the focus of our review is quality improvement strategies, we will also include all published and unpublished non-randomised controlled trials (NRCTs), controlled before-after studies (CBAs), and interrupted time series (ITS) studies. We will exclude any ITS study that does not have a clearly-defined point in time when the intervention occurred, and does not have at least three data points before and three data points after the intervention (EPOC 2002b).
Types of participants
In this review, we will include interventions targeting primary care facilities and primary care providers. We use a broad definition of primary care that includes "all general health facilities which cover a broad range of presenting ailments which can be accessed by a wide range of patients on demand and not as a result of referral for specialist care" (Kaner 2007; Sanz-Cuesta 2012). We use this broad definition because in many low-and middle-income countries (LMICs), a significant proportion of patients access a range of health providers and facilities including private and public health outpatient/ambulatory facilities and pharmacies as their first point of entry to care (Marek 2005). The participants include:
1. Primary care facilities (including general practices, genitourinary medicine clinics, family planning clinics, community sexual health services, community pharmacies, and outpatient/ambulatory clinics); and 2. Primary care providers (including general practitioners, family practitioners, family physicians, nurses, community health workers, and community pharmacists). We will include non-medical personnel including pharmacists and community health workers as long as they fit into the definition of primary care providers as defined above.
Types of interventions
We will include interventions that improve delivery of sexual health services for chlamydia, gonorrhoea, trichomoniasis and syphilis within primary care facilities and with primary care providers. We will classify the interventions implemented in the included studies as professional, organisational, financial and regulatory interventions in accordance with the Cochrane Effective Practice and Organisation of Care Group (EPOC) taxonomy of interventions (see EPOC 2002). Patient-oriented financial interventions including user fees, patient incentives, and co-payments, and patient-oriented organisational interventions such as mailorder pharmacies will be excluded from this review. Appendix 1 presents all of the categories of interventions that will be included in this review. Consideration will be given to the intervention/s or combinations of interventions that were delivered, their intensity and frequency, who delivered the intervention, and the duration of the intervention. Comparisons will be made between the following:
• single intervention compared with standard practice or no intervention;
• single intervention compared with another single intervention;
• single intervention compared with multifaceted intervention (any combination, dose, frequency, duration, intensity);
• multifaceted intervention (any combination, dose, frequency, duration, intensity) compared with standard practice or no intervention.
Types of outcome measures
The outcomes in the selected studies will depend on the local guidelines for each country/jurisdiction and also on the STI. Depending on the study design, comparisons of outcomes may be made between services or within the same service over time. For each type of infection, the following outcomes will be considered:
Primary outcomes
• Proportion of the target population screened/tested (effective screening rate).
• Average time to treatment.
• Proportion of cases rescreened/tested at three months.
• Proportion of the target population tested annually.
Secondary outcomes
• Proportion of diagnosed patients treated.
• Proportion of tests with a positive result (test positivity).
• Proportion of cases with confirmed contact tracing/partner notification.
• Proportion of cases re-infected.
• Proportion of cases notified to a central service.
• Proportion of false positives.
• Harm to patients, for example partner violence, abuse or suicide.
• Health professional outcomes: changes with regard to health professionals' behaviour, knowledge, attitudes or satisfaction.
• Prevalence and incidence of STIs.
• Incidence of pelvic inflammatory disease (women) and epididymitis (men) secondary to chlamydia.
• Health service outcome: costs.
• Adverse events
Search methods for identification of studies
We will develop a highly sensitive search strategy to identify as many relevant Randomized Controlled Trials (RCTs) and non-RCT designs as possible of quality improvement interventions for improving the detection and management of curable STIs in primary care, irrespective of their language, publication date and publication status (published, unpublished, in press, and in progress). We will use both electronic searching in bibliographic databases and handsearching, as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). The results of all searches will be downloaded and managed using Endnote bibliographic software. Duplicate records of the same study will be deleted.
Electronic searches
We will contact the information specialist of the Sexually Transmitted Infections Cochrane Review Group in order to implement a comprehensive search strategy to capture as many relevant RCTs and non RCTs as possible in electronic databases. For this purpose, we will use a combination of exploded controlled vocabulary (MeSH, Emtree, DeCS) and free-text terms (considering spelling variants, plurals, synonyms, acronyms and abbreviations), with field labels, truncation, proximity operators and boolean operators. The search strategy for MEDLINE, EMBASE and LILACS can be found in Appendix 2 (Electronic search strategies). We will modify the search strategy for other databases using appropriate syntax and vocabulary for those databases. Specifically, we will search in the following electronic databases:
• MEDLINE, Ovid platform: inception to present.
• MEDLINE In-Process & Other Non-Indexed Citations, Ovid platform: inception to present.
• MEDLINE Daily Update, Ovid platform: inception to present.
• EMBASE.com: inception to present.
• The Cochrane Central Register of Controlled Trials (CENTRAL), Ovid platform: inception to present.
• LILACS, iAHx interface: inception to present.
• PsycINFO: inception to present.
• African Index Medicus (AIM), Virtual Health Library (VHL): inception to present.
• CINAHL (Cumulative Index to Nursing and Allied Health Literature): inception to present We will use for MEDLINE, Cochrane highly sensitive search strategy for identifying RCTs: sensitivity and precision maximizing version (2008 revision), Ovid format (Higgins 2011), and an the Effective Practice and Organisation of Care (EPOC) methodology filter to identify non-RCT designs (Steed 2014). These searches will be updated within six months before publication of the review.
Searching other resources
We will attempt to identify additional relevant RCTs and non-RCTs studies by using of the following methods: 1. Searching in the Sexually Transmitted Infections Cochrane Review Group's Specialized Register, which includes RCTs and controlled clinical trials, from 1944 to 2014, located through:
• Electronic searching in MEDLINE, EMBASE and CENTRAL.
• Online handsearching in those journals not indexed in MEDLINE or EMBASE, according to the journals' master list of the STI Cochrane Review Group.
• WHO International Clinical Trials Registry Platform ICTRP portal (http://apps.who.int/trialsearch/): inception to present. 8. Handsearching within previous systematic reviews and other relevant publications on the same topic. 9. Handsearching within reference lists of all relevant RCTs identified by others methods.
Data collection and analysis
Selection of studies
Using a form with predefined inclusion criteria, two review authors, Barbara Nattabi (BN) and Alice Rumbold (AR), will independently assess all the titles and abstracts of the studies for eligibility. We will assess and obtain full-text manuscripts for those studies that we agree are potentially eligible. For those articles for which we cannot agree, we will obtain the full text of the article to determine eligibility. If there are insufficient data in the reports to determine eligibility, we will contact the relevant authors for extra information. We will resolve all disagreements with discussion, and consultation with the third review author, Sajni Gudka (SG).
Data extraction and management
Two authors (BN, AR) will independently extract data using a specially designed standardised extraction form based on the Cochrane STI Group and EPOC Group data collection sheets. We will pilot the form with a representative number of studies and modify it if there are any missing data. The authors will extract data from every report associated with each eligible study. In instances where there is a single main report and a multitude of smaller reports of the same study, the data will be merged directly into a single data collection form. If there are multiple detailed manuscripts of the same study, data will be extracted from the most comprehensive report and extra data from the other reports will be extracted and included into a single data collection form. We will resolve any discrepancies through discussion or adjudication by the third author, SG. Articles in languages other than English will be translated and data extracted in the process described above. We will extract data on: the authors and citation; location of study and setting (low-, middle-and high-income countries); regional location of service (rural, urban); ethical approval; study design (randomised, non-randomised; CBA; ITS); inclusion and exclusion criteria; methods (duration, sequence generation, allocation sequence concealment, blinding); characteristics of study participants (primary care facilities and primary care providers); population risk profile (high, low or unclear risk of contracting an STI, as defined by authors); type of STI (chlamydia, gonorrhoea, trichomoniasis, syphilis); type and components of the intervention (professional, financial, organisational, regulatory); type and components of the comparison intervention; and outcomes (primary and secondary). 
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias for each included RCT study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions using the Cochrane Collaboration's 'Risk of bias' tool (Higgins 2011). We will use the ROBINS-I tool (Risk Of Bias In Non-randomized Studies -of Interventions) to assess the risk of bias in the non-randomised trials (Sterne 2014). Any disagreement will be resolved by discussion or by involving a third author. The domains that we will assess for risk are:
(1) Random sequence generation (checking for possible selection bias) We will describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. We will assess the methods as:
• low risk of bias (any truly random process, e.g. random number table; computer random number generator);
• high risk of bias (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection bias) We will describe for each included study the method used to conceal allocation to interventions prior to assignment and assess whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We will assess the methods as:
• low risk of bias (e.g. telephone or central randomisation; consecutively-numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or nonopaque envelopes, alternation; date of birth);
(3.1) Blinding of participants and personnel (checking for possible performance bias)
We will describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We will consider that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding was unlikely to affect results. We will assess blinding separately for different outcomes or classes of outcomes. We will assess the methods as:
• low, high or unclear risk of bias for participants; • low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible detection bias)
We will describe for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We will assess blinding separately for different outcomes or classes of outcomes. We will assess methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition bias due to the amount, nature and handling of incomplete outcome data) We will describe for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We will state whether attrition and exclusions were reported and the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information is reported, or can be supplied by the trial authors, we plan to re-include missing data in the analyses. We will assess methods as:
• low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation);
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found. We will assess the methods as:
• low risk of bias (where it is clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review have been reported);
• high risk of bias (where not all the study's pre-specified outcomes have been reported; one or more reported primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot be used; the study fails to include results of a key outcome that would have been expected to have been reported);
(6) Other bias (checking for bias due to problems not covered by (1) to (5) above)
We will describe for each included study any important concerns we have about other possible sources of bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies were at high risk of bias, according to the criteria given in the Cochrane Handbook (Higgins 2011). With reference to (1) to (6) above, we plan to assess the likely magnitude and direction of the bias and whether we consider it is likely to impact on the findings. We plan to explore the impact of the level of bias through undertaking sensitivity analyses -see Sensitivity analysis.
Risk of bias in cross-over trials
In addition we shall assess for risk in cross-over trials, specifically:
• if use of a cross-over trial was appropriate for the study; • if the order of receiving the intervention was randomised;
• if the trial was not biased from carry-over effects; and • if unbiased data are available (Higgins 2011).
Risk of bias in controlled before-after and interrupted time series studies
In addition to using the ROBINS-I tool to assess the risk of bias in CBA and ITS studies, ITS studies will be assessed using seven extra criteria:
• if the intervention was independent of other changes; • if the shape of the intervention effect was pre-specified;
• if the intervention was unlikely to affect data collection;
• if knowledge of the allocated interventions was adequately prevented during the study;
• if incomplete outcome data were adequately addressed;
• if the study was free from selective outcome reporting;
• if the study was free from other risks of bias (EPOC 2008).
Measures of treatment effect
For dichotomous data, the results will be presented as a summary risk ratio (RR) with 95% confidence intervals (CIs). For studies that report continuous outcomes that are measured in the same way, we will use the mean difference. For studies that use different methods to assess the same outcome, we will use the standardised mean difference. For time-to-event outcomes, we will present treatment effects as overall hazard ratios with 95% CIs.
Unit of analysis issues
Randomised trials
We plan to include cluster-randomised trials as well as individually-randomised trials. For cluster-randomised trials, we will adjust the sample size using the methods described in the Cochrane Handbook (Higgins 2011) using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial or from a study of a similar population. If we use ICCs from other sources, we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify both cluster-randomised trials and individually-randomised trials, we plan to synthesise the relevant information. We will consider it reasonable to combine the results from both if there is little heterogeneity between the study designs, and the interaction between the effect of the intervention and the choice of randomisation unit is considered to be unlikely.
Multi-arm studies
If we identify eligible multi-arm studies (more than one treatment group), we will combine treatment groups if appropriate, and create a single pair-wise comparison. We will not double count partic-ipants, according to the methods described in the Cochrane Handbook (Higgins 2011).
Dealing with missing data
If data related to the methods are missing, or if the methods are not clear, we will contact the original investigators for clarification. If outcome data are missing, we will contact the original investigators to request the missing data. If we fail to obtain missing outcome data, we will conduct an analysis on the outcome variables on an intention-to-treat basis, i.e. we aim to include all participants as they were randomised, regardless of what occurred subsequently. Where summary data are missing, we will calculate or estimate the missing value from available statistics in the paper. For instance we will calculate the standard deviation from standard errors, confidence intervals, t values and P values. If these statistics are not available, we will impute the missing values e.g. we will use standard deviations from one or more other studies in the meta-analysis or from other studies in another meta-analysis (Higgins 2011). However, imputation of standard deviations will not be conducted if a majority of studies have missing standard deviations. We will report the assumptions we have made in our results tables.
Assessment of heterogeneity
We will make an assessment of whether to conduct a meta-analysis by assessing for heterogeneity between the included studies. We will conduct a visual inspection of the forest plots and use the Chi 2 test and I 2 statistic to measure the level of heterogeneity. We will consider that heterogeneity is substantial, and hence meta-analysis impossible, if the CIs of the effect estimates of the individual studies have significantly poor overlap, if I 2 is greater than 40% or if the P value is less than 0.10 in the Chi 2 test for heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis we will investigate reporting biases (such as publication bias) using funnel plots. We will assess funnel plot asymmetry visually, as well as using formal tests. For continuous outcomes we will use the test proposed by Egger 1997, and for dichotomous outcomes we will use the test proposed by Harbord 2006. If we detect asymmetry in any of these tests or it is suggested by a visual assessment, we will perform exploratory analyses to investigate it.
Data synthesis
We will use narrative synthesis to describe the results of trials where there are too few studies for meta-analysis or where we consider that meta-analysis is not clinically meaningful. We will use forest plots to display results of trials examining the same outcome. If we can reasonably assume that the studies are estimating the same intervention and the studies' population and methods are judged sufficiently similar, we will use a fixed-effect meta-analysis for combining data. However we expect to find considerable heterogeneity due to diversity in countries, health systems, participants (primary healthcare services and providers), interventions being evaluated and study designs. Furthermore we expect that many eligible studies such as cluster-randomised studies will have 'unit of analysis' errors. If we detect considerable heterogeneity, or there are too few studies, we will not perform meta-analysis to combine the data. Should we have a sufficient number of comparable studies, i.e. based on population, study design, intervention and comparisons, we will separate our analysis by RCTs, NRCTs, CBAs and ITS. For RCTs, we will use a random-effects model to estimate the average effect across trials as we expect that the studies will be naturally heterogeneous. The results will be presented as the summary RR (95% CI) with I 2 and tau 2 estimates for outcomes reporting dichotomous data. We will calculate the mean difference for outcomes reporting continuous data. If it is possible to conduct a meta-analysis with at least three studies using a random-effects model, we will also calculate a prediction interval. A prediction interval is a CI which takes into account heterogeneity and provides a wider predicted range for the true treatment effect of an intervention in an individual setting, making it of more relevance to clinical practice and decision making (Riley 2011). We will initially include all trials and conduct a sensitivity analysis, excluding any non-randomised studies. If the non-randomised studies are deemed relatively homogenous with a low risk of bias, we will similarly combine data using meta-analysis. For the metaanalysis of non-randomised studies we will use the estimated intervention effect and its standard error (or CI) and data will be pooled using the generic inverse-variance method (Higgins 2011). All statistical analysis will be carried out using the Review Manager software (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
For data that can be included in a meta-analysis, we plan to investigate any identified heterogeneity using subgroup analyses and sensitivity analyses. If substantial heterogeneity is detected, we will first consider whether it is meaningful to calculate an overall summary effect measure, and if so, we will use a random-effects analysis to do so.
We will carry out the following subgroup analyses for primary outcomes:
1. location of study (low-, middle-and high-income countries) 2. regional location of service (rural, urban) 3. characteristics of study participants (primary care facilities and primary care providers); 4. population risk profile (high, low or unclear risk of contracting an STI as defined by the study authors); 5. type and components of the intervention (professional, financial, organisational, regulatory). Where data can be included in a meta-analysis, we will assess subgroup differences by interaction tests available within RevMan (RevMan 2014). We will report the results of subgroup analyses quoting the Chi 2 statistic and P value, and the interaction test I 2 value.
Sensitivity analysis
We will carry out sensitivity analyses to explore the effect of study quality assessed by concealment of allocation (where applicable), high attrition rates, or both. Studies with high risk of bias will be excluded from the meta-analysis in order to assess whether this made any difference to the overall result. Where cluster-randomised studies are included we will also perform a sensitivity analysis based on the unit of randomisation. The sensitivity analyses will also compare the results of the meta-analysis of randomised trials with the meta-analysis of non-randomised trials, to determine the influence of difference study designs on the overall effect estimate. For studies that could not be included in a meta-analysis, we will descriptively compare the results of studies with high risk of bias and studies with low risk of bias.
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The authors thank the Cochrane Sexually Transmitted Infections editorial team for their support, advice and assistance throughout the preparation of this protocol. Barbara Nattabi is supported by a NHMRC Early Career Research Fellowship and Alice Rumbold is supported by a NHMRC Career Development Fellowship. The Western Australian Centre for Rural Health receives funding from the Australian Federal Department of Health. c. Local consensus processes : inclusion of participating providers in discussion to ensure that they agreed that the chosen clinical problem was important and the approach to managing the problem was appropriate. d. Educational outreach visits: use of a trained person who met with providers in their practice settings to give information with the intent of changing the provider's practice. The information given may have included feedback on the performance of the provider(s). e. Local opinion leaders: use of providers nominated by their colleagues as 'educationally influential'. The investigators must have explicitly stated that their colleagues identified the opinion leaders. f. Patient-mediated interventions: new clinical information (not previously available) collected directly from patients and given to the provider, e.g. depression scores from an instrument. g. Audit and feedback : any summary of clinical performance of health care over a specified period of time. The summary may also have included recommendations for clinical action. The information may have been obtained from medical records, computerised databases, or observations from patients. The following interventions are excluded:
• Provision of new clinical information not directly reflecting provider performance which was collected from patients, e.g. scores on a depression instrument, abnormal test results. These interventions should be described as patient mediated.
• Feedback of individual patients' health record information in an alternate format (e.g. computerised). These interventions should be described as organisational.
h. Reminders: Patient-or encounter-specific information, provided verbally, on paper or on a computer screen, which is designed or intended to prompt a health professional to recall information. This would usually be encountered through their general education; in the medical records or through interactions with peers, and so remind them to perform or avoid some action to aid individual patient care. Computer-aided decision support and drugs dosage are included. i. Marketing: Use of personal interviewing, group discussion ('focus groups'), or a survey of targeted providers to identify barriers to change and subsequent design of an intervention that addresses identified barriers. j. Mass media: (i) varied use of communication that reached great numbers of people including television, radio, newspapers, posters, leaflets, and booklets, alone or in conjunction with other interventions; (ii) targeted at the population level. k. Other 2. Financial interventions a. Provider interventions i. Fee-for-service : provider has been paid for number and type of service delivered. ii. Prepaid: no other description. iii. Capitation: provider was paid a set amount per patient for providing specific care. iv. Provider salaried service: provider received basic salary for providing specific care. v. Prospective payment : provider was paid a fixed amount for health care in advance. vi. Provider incentives: provider received direct or indirect financial reward or benefit for doing specific action. vii. Institution incentives: institution or group of providers received direct or indirect financial rewards or benefits for doing specific action. viii. Provider grant/allowance: provider received direct or indirect financial reward or benefit not tied to specific action. ix. Institution grant/allowance: institution or group of providers received direct or indirect financial reward or benefit not tied to specific action. #131.'pre post':ab,ti OR 'pre test':ab,ti OR pretest*:ab,ti OR posttest*:ab,ti OR 'post test':ab,ti OR (pre NEAR/5 post):ab,ti #132.'pre workshop':ab,ti OR 'post workshop':ab,ti OR (before NEAR/3 workshop):ab,ti OR (after NEAR/3 workshop):ab,ti #133.trial:ti OR (study NEAR/3 aim*):ab OR 'our study':ab #134.(before NEAR/10 (after OR during)):ab,ti #135.'quasi-experiment':ab,ti OR quasiexperiment*:ab,ti OR 'quasi random':ab,ti OR quasirandom*:ab,ti OR 'quasi control':ab,ti OR quasicontrol*:ab,ti OR ((quasi* OR experimental) NEAR/3 (method* OR study OR trial OR design*)):ab,ti #136.('time series' NEAR/2 interrupt*):ab,ti #137.time:ab AND (points NEAR/3 (over OR multiple OR three OR four OR five OR six OR seven OR eight OR nine OR ten OR eleven OR twelve OR month* OR hour* OR day* OR 'more than')):ab #138.pilot:ti #139.'pilot study'/exp #140.'clinical trial':ti OR 'controlled clinical trial':ti OR 'multicenter study':ti #141.multicentre:ti OR multicenter:ti OR 'multi-centre':ti OR 'multi-center':ti #142.random*:ab,ti OR controlled:ti #143.(control NEAR/3 (area OR cohort* OR compare* OR condition OR design OR group* OR intervention* OR participant* OR study)):ab NOT ('controlled clinical trial':ab,ti OR 'randomized controlled trial':ab,ti) #144.control:ab,ti AND year*:ab,ti experimental:ab,ti AND year*:ab,ti OR 'control period*':ab,ti OR 'experimental period*':ab,ti #145.'prospective study'/de OR 'retrospective study'/de #146.utilization:ti OR programme:ti OR programmes:ti #147.(during NEAR/5 period):ab,ti #148.((strategy OR strategies) NEAR/2 (improv* OR education*)):ab,ti #149.(purpose NEAR/3 study):ab #150.'comment on':ab,ti OR 'review'/it OR (review:ti NOT 'peer review':ti) OR 'randomized controlled trial (topic)'/de #151.rat:ab,ti OR rats:ab,ti OR cow:ab,ti OR cows:ab,ti OR chicken*:ab,ti OR horse:ab,ti OR horses:ab,ti OR mice:ab,ti OR mouse: ab,ti OR bovine:ab,ti OR animal*:ab,ti OR veterinary*:ab,ti #153 OR/.#127-#152 #154.#150 OR #151 OR #152 #155.#153 NOT #154 #156.#126 AND #155 #157.#126 AND #155 AND [embase]/lim [non-RCT results] #158.#125 AND #126 #159. #125 AND #126 AND [embase]/lim [RCT results] LILACS (iAHx interface) (mh:("Sexually Transmitted Diseases")) AND (ti:("quality")) OR (ab:("quality")) AND db:("LILACS") WHO International Clinical Trials Registry Platform ICTRP portal quality AND chlam* OR gonorrh* OR syphili* OR trichomon* OR venere* or sex infection* ClinicalTrials.gov quality AND "Sexually Transmitted Diseases" (by topic)
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